In Ohio, Compound Laws tracks 19 compounds: 4 legal to sell at retail, 3 restricted, 2 in a gray area, 5 illegal, and 5 whose status varies by product form. Verified through October 22, 2026.
a51c2f62c2f7c543**OAC 4729:9-1-01(D) (hallucinogen scope)** — "Any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances, including their salts, isomers, and salts of isomers, unless specifically excepted under federal drug abuse control laws … (29) Psilocybin; (30) Psilocyn;" — OAC 4729:9-1-01(D), https://codes.ohio.gov/ohio-administrative-code/rule-4729:9-1-01 (OFFICIAL, eff. Nov. 8, 2025). 4-HO-MET does not appear; the only structural catch-alls in the rule are non-tryptamine. **R.C. 3719.013 (analog treatment)** — "a controlled substance analog, to the extent intended for human consumption, shall be treated for purposes of any provision of the Revised Code as a controlled substance in schedule I." — R.C. 3719.013, https://codes.ohio.gov/ohio-revised-code/section-3719.013 (OFFICIAL, eff. Dec. 20, 2012). The "controlled substance analog" definition (R.C. 3719.01) uses the federal-style "substantially similar chemical structure" + "substantially similar … hallucinogenic effect" to a Schedule I/II substance.
629bd14f29d13383The following are classified as schedule I controlled substances: (A) Mitragynine-related compounds, whether synthetic or naturally occurring substances contained in the plant, or in the resinous extractives of mitragyna speciosa (also known as kratom) and/or synthetic substances, derivatives, prodrugs, isomers, esters, ethers, salts and salts of isomers, esters and ethers with similar chemical structure. Mitragynine-related compounds include, but are not limited to, the following: 7-hydroxymitragynine; mitragynine pseudoindoxyl; dihydro-7-hydroxy mitragynine; and 7-acetoxymitragynine. Mitragynine-related compounds do not include any of the following: (1) Any dangerous drug that is the subject of an application approved by the [FDA] under subsections 505(c) or (j) of the [FD&C Act] ... for marketing as a dangerous drug; (2) Any compound used in food consistent with either: (a) A food additive regulation published in the [CFR]; or (b) A "no questions response" issued by the [FDA] in response to a [GRAS] notice. (3) Any drug approved by the [FDA] ... that may be lawfully sold over the counter without a prescription in accordance with section 505G of the [FD&C Act] ...; (4) Mitragynine.
6c140edf84af933dAs used in this chapter: (A) "Container" means the innermost wrapping, packaging, or vessel in direct contact with a final hemp-derived cannabinoid product in which the final hemp-derived cannabinoid product is enclosed for retail sale to consumers, such as a jar, bottle, bag, box, packet, can, carton, or cartridge. "Container" does not include bulk shipping containers or outer wrappings that are not essential for the final retail delivery or sale to an end consumer for personal or household use. (C) "Hemp" means the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a total tetrahydrocannabinols concentration, including tetrahydrocannabinolic acid, of not more than three-tenths per cent on a dry weight basis. "Hemp" includes industrial hemp. "Hemp" does not include any of the following: (1) Any viable seeds from a Cannabis sativa L. plant that exceeds a total tetrahydrocannabinols concentration, including tetrahydrocannabinolic acid, of three-tenths per cent in the plant on a dry weight basis; (2) Any intermediate hemp-derived cannabinoid product containing any of the following: (a) Cannabinoids that are not capable of being naturally produced by a Cannabis sativa L. plant; (b) Cannabinoids that are capable of being naturally produced by a Cannabis sativa L. plant and were synthesized or manufactured outside the plant; (c) More than three-tenths per cent combined total of total tetrahydrocannabinols, including tetrahydrocannabinolic acid, and any other cannabinoids that have similar effects or are marketed to have similar effects on humans or animals as a tetrahydrocannabinol as established by the superintendent of cannabis control in lists adopted under section 928.031 of the Revised Code. (3) Any intermediate hemp-derived cannabinoid product that is marketed or sold as a final product or directly to an end consumer for personal or household use; (4) Any final hemp-derived cannabinoid product containing any of the following: (a) Cannabinoids that are not capable of being naturally produced by a Cannabis sativa L. plant; (b) Cannabinoids that are capable of being naturally produced by a Cannabis sativa L. plant and were synthesized or manufactured outside the plant; (c) Greater than four-tenths of a milligram combined total per container of total tetrahydrocannabinols, including tetrahydrocannabinolic acid, and any other cannabinoids that have similar effects, or are marketed to have similar effects, on humans or animals as a tetrahydrocannabinol as established by the superintendent of cannabis control in lists adopted under section 928.031 of the Revised Code. (E) "Hemp-derived cannabinoid product" means any intermediate or final product derived from hemp, other than industrial hemp, that contains cannabinoids in any form and is intended for human or animal use through any means of application or administration, such as inhalation, ingestion, or topical application. "Hemp-derived cannabinoid product" does not include a drug that is the subject of an application approved under subsection (c) or (j) of 21 U.S.C. 355. (H) "Intermediate hemp-derived cannabinoid product" means a hemp-derived cannabinoid product that is either of the following: (1) Not yet in the final form or preparation marketed or intended to be used or consumed by a human or animal; (2) A powder, liquid, tablet, oil, or other product form that is intended or marketed to be mixed, dissolved, formulated, or otherwise added to or prepared with or into any other substance prior to administration or consumption.
6c140edf84af933dAs used in this chapter: (A) "Container" means the innermost wrapping, packaging, or vessel in direct contact with a final hemp-derived cannabinoid product in which the final hemp-derived cannabinoid product is enclosed for retail sale to consumers, such as a jar, bottle, bag, box, packet, can, carton, or cartridge. "Container" does not include bulk shipping containers or outer wrappings that are not essential for the final retail delivery or sale to an end consumer for personal or household use. (C) "Hemp" means the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a total tetrahydrocannabinols concentration, including tetrahydrocannabinolic acid, of not more than three-tenths per cent on a dry weight basis. "Hemp" includes industrial hemp. "Hemp" does not include any of the following: (1) Any viable seeds from a Cannabis sativa L. plant that exceeds a total tetrahydrocannabinols concentration, including tetrahydrocannabinolic acid, of three-tenths per cent in the plant on a dry weight basis; (2) Any intermediate hemp-derived cannabinoid product containing any of the following: (a) Cannabinoids that are not capable of being naturally produced by a Cannabis sativa L. plant; (b) Cannabinoids that are capable of being naturally produced by a Cannabis sativa L. plant and were synthesized or manufactured outside the plant; (c) More than three-tenths per cent combined total of total tetrahydrocannabinols, including tetrahydrocannabinolic acid, and any other cannabinoids that have similar effects or are marketed to have similar effects on humans or animals as a tetrahydrocannabinol as established by the superintendent of cannabis control in lists adopted under section 928.031 of the Revised Code. (3) Any intermediate hemp-derived cannabinoid product that is marketed or sold as a final product or directly to an end consumer for personal or household use; (4) Any final hemp-derived cannabinoid product containing any of the following: (a) Cannabinoids that are not capable of being naturally produced by a Cannabis sativa L. plant; (b) Cannabinoids that are capable of being naturally produced by a Cannabis sativa L. plant and were synthesized or manufactured outside the plant; (c) Greater than four-tenths of a milligram combined total per container of total tetrahydrocannabinols, including tetrahydrocannabinolic acid, and any other cannabinoids that have similar effects, or are marketed to have similar effects, on humans or animals as a tetrahydrocannabinol as established by the superintendent of cannabis control in lists adopted under section 928.031 of the Revised Code. (E) "Hemp-derived cannabinoid product" means any intermediate or final product derived from hemp, other than industrial hemp, that contains cannabinoids in any form and is intended for human or animal use through any means of application or administration, such as inhalation, ingestion, or topical application. "Hemp-derived cannabinoid product" does not include a drug that is the subject of an application approved under subsection (c) or (j) of 21 U.S.C. 355. (H) "Intermediate hemp-derived cannabinoid product" means a hemp-derived cannabinoid product that is either of the following: (1) Not yet in the final form or preparation marketed or intended to be used or consumed by a human or animal; (2) A powder, liquid, tablet, oil, or other product form that is intended or marketed to be mixed, dissolved, formulated, or otherwise added to or prepared with or into any other substance prior to administration or consumption.
eda464f28d51571e(C) "Hemp" means the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a total tetrahydrocannabinols concentration, including tetrahydrocannabinolic acid, of not more than three-tenths per cent on a dry weight basis. "Hemp" includes industrial hemp. "Hemp" does not include any of the following: (1) Any viable seeds from a Cannabis sativa L. plant that exceeds a total tetrahydrocannabinols concentration, including tetrahydrocannabinolic acid, of three-tenths per cent in the plant on a dry weight basis; (2) Any intermediate hemp-derived cannabinoid product containing any of the following: (a) Cannabinoids that are not capable of being naturally produced by a Cannabis sativa L. plant; (b) Cannabinoids that are capable of being naturally produced by a Cannabis sativa L. plant and were synthesized or manufactured outside the plant; (c) More than three-tenths per cent combined total of total tetrahydrocannabinols, including tetrahydrocannabinolic acid, and any other cannabinoids that have similar effects or are marketed to have similar effects on humans or animals as a tetrahydrocannabinol as established by the superintendent of cannabis control in lists adopted under section 928.031 of the Revised Code. (3) Any intermediate hemp-derived cannabinoid product that is marketed or sold as a final product or directly to an end consumer for personal or household use; (4) Any final hemp-derived cannabinoid product containing any of the following: (a) Cannabinoids that are not capable of being naturally produced by a Cannabis sativa L. plant; (b) Cannabinoids that are capable of being naturally produced by a Cannabis sativa L. plant and were synthesized or manufactured outside the plant; (c) Greater than four-tenths of a milligram combined total per container of total tetrahydrocannabinols, including tetrahydrocannabinolic acid, and any other cannabinoids that have similar effects, or are marketed to have similar effects, on humans or animals as a tetrahydrocannabinol as established by the superintendent of cannabis control in lists adopted under section 928.031 of the Revised Code.
373ca483b7ef4bbeSec. 3719.013. Except as otherwise provided in section 2925.03 or 2925.11 of the Revised Code, a controlled substance analog, to the extent intended for human consumption, shall be treated for purposes of any provision of the Revised Code as a controlled substance in schedule I. Sec. 3719.01(Z)(1) "Controlled substance analog" means, except as provided in division (Z)(2) of this section, a substance to which both of the following apply: (a) The chemical structure of the substance is substantially similar to the structure of a controlled substance in schedule I or II. (b) One of the following applies regarding the substance: (i) The substance has a stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance in schedule I or II. (ii) With respect to a particular person, that person represents or intends the substance to have a stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance in schedule I or II. (2) "Controlled substance analog" does not include any of the following: (a) A controlled substance; (b) Any substance for which there is an approved new drug application; (c) With respect to a particular person, any substance if an exemption is in effect for investigational use for that person pursuant to federal law to the extent that conduct with respect to that substance is pursuant to that exemption; (d) Any substance to the extent it is not intended for human consumption before the exemption described in division (Z)(2)(b) of this section takes effect with respect to that substance.
5ca11dce0915c0e2928.01 (C) "'Hemp' means the plant Cannabis sativa L. and any part of that plant" [...] [with a total THC concentration] "of not more than three-tenths per cent on a dry weight basis" [where total THC means] "total tetrahydrocannabinols, including tetrahydrocannabinolic acid". (C)(4) [Hemp does not include final hemp-derived cannabinoid products containing:] (a) "Cannabinoids that are not capable of being naturally produced by a Cannabis sativa L. plant" [...] (c) "Greater than four-tenths of a milligram combined total per container of total tetrahydrocannabinols" [...]. (E) ["Hemp-derived cannabinoid product" means] "any intermediate or final product derived from hemp, other than industrial hemp" [intended for human or animal use by means] "such as inhalation, ingestion, or topical application". [Bracketed spans summarized; authenticated PDF dated 3-20-2026.]
Compound Laws, published by Compound Analytics, reports the record: statutes verbatim, official citations, enforcement facts and verification dates. Nothing here is legal advice and nothing here describes how to get around a law. A jurisdiction with no verified row is reported as not yet verified, never as legal. Found an error? Corrections policy.
About · Methodology · Glossary · Changes · Data & API · llms.txt · Sitemap